Proactive Investors - Run By Investors For Investors

Cellmid 'on track for record revenues' in FY19, targeting profitability in FY20

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive Investors the major achievements since raising $10 million in September last year, and details the next phases of growth.

Cellmid is a life sciences company with a consumer business that has consistently delivered double digit revenue growth and is heading towards profitability. It is also the owner and developer of the largest intellectual property portfolio around midkine; a drug target indicated in cancer, inflammatory diseases and fibrosis.

View full CDY profile View Profile

Cellmid Ltd Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use